Article Details
Retrieved on: 2022-06-13 21:25:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies.
Article found on: www.neurologylive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here